Duncan McKechnie net worth and biography

Duncan McKechnie Biography and Net Worth

Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals

Duncan joined Vertex in 2013. As Vertex’s Executive Vice President and Chief Commercial Officer (CCO), he oversees Vertex’s global commercial team, which includes activities that support the approved use of Vertex’s marketed medicines around the world. Prior to becoming CCO, he led the North America Commercial team and oversaw Marketing, Sales, Market Access and Patient Support in the United States and Canada. He also held leadership responsibility for the Global Health Economics and Global Pricing and Market Access functions across the Vertex portfolio.

He graduated with a degree in business studies from the University of Plymouth in the United Kingdom, and prior to Vertex, he held multiple commercial leadership roles of increasing responsibility at Novartis where he worked for over 13 years in the UK, Switzerland and the U.S.

What is Duncan McKechnie's net worth?: The estimated net worth of Duncan McKechnie is at least $8.43 million as of February 25th, 2026. Mr. McKechnie owns 17,559 shares of Vertex Pharmaceuticals stock worth more than $8,430,603 as of February 27th. This net worth evaluation does not reflect any other assets that Mr. McKechnie may own. Learn More about Duncan McKechnie's net worth.
How do I contact Duncan McKechnie?: The corporate mailing address for Mr. McKechnie and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Duncan McKechnie's contact information.
Has Duncan McKechnie been buying or selling shares of Vertex Pharmaceuticals?: During the last quarter, Duncan McKechnie has sold $2,394,361.50 in shares of Vertex Pharmaceuticals stock. Most recently, Duncan Mckechnie sold 4,910 shares of the business's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a transaction totalling $2,394,361.50. Following the completion of the sale, the executive vice president now directly owns 17,559 shares of the company's stock, valued at $8,562,646.35. Learn More on Duncan McKechnie's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Mark Bunnage (Executive Vice President and Chief Scientific Officer), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Duncan McKechnie (Executive Vice President and Chief Commercial Officer), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, Vertex Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $1,948,400.00. During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 246,042 shares worth more than $112,061,826.68. The most recent insider tranaction occured on February, 25th when EVP Ourania Tatsis sold 260 shares worth more than $126,451.00. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 2/25/2026.

Duncan McKechnie Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/25/2026	Sell	4,910	$487.65	$2,394,361.50	17,559

Duncan McKechnie Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $487.96

$479.75

$489.05

50 Day Range

MA: $465.74

$438.92

$491.47

2 Week Range

Now: $487.96

$362.50

$519.68

Volume

86,544 shs

Average Volume

1,484,908 shs

Market Capitalization

$123.96 billion

P/E Ratio

31.77

Dividend Yield

N/A

Beta

0.3